| 1 |
35431974 | Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance. | 2022 |
1 |
| 2 |
34101105 | HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib. | 2021 Dec |
3 |
| 3 |
32490320 | Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. | 2020 Jun |
2 |
| 4 |
32795383 | Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib. | 2020 Aug 14 |
1 |
| 5 |
33176309 | Lapatinib Decreases the Preimplantation Aneuploidy Rate of in vitro Fertilized Mouse Embryos without Affecting Completion of Preimplantation Development. | 2020 |
1 |
| 6 |
30786890 | Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. | 2019 Feb 20 |
2 |
| 7 |
31209328 | Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. | 2019 Jul |
1 |
| 8 |
30125265 | Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. | 2018 Aug 20 |
4 |
| 9 |
30279968 | Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. | 2018 Sep 7 |
1 |
| 10 |
28061785 | Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. | 2017 Jan 6 |
6 |
| 11 |
29109274 | Near-infrared remotely triggered drug-release strategies for cancer treatment. | 2017 Nov 21 |
1 |
| 12 |
26692570 | Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. | 2016 Mar 1 |
1 |
| 13 |
27197158 | Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. | 2016 Aug 15 |
1 |
| 14 |
27293993 | Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. | 2016 |
1 |
| 15 |
25347743 | Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems. | 2015 Jul 30 |
1 |
| 16 |
25375038 | ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. | 2015 Jan |
3 |
| 17 |
25700543 | The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. | 2015 Apr 30 |
1 |
| 18 |
26086099 | Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice. | 2015 Aug 7 |
1 |
| 19 |
26261492 | Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. | 2015 |
3 |
| 20 |
26337386 | Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. | 2015 Nov 5 |
3 |
| 21 |
26474677 | A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. | 2015 Dec 28 |
6 |
| 22 |
24384723 | HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. | 2014 Jan 2 |
2 |
| 23 |
24451154 | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. | 2014 Jan 23 |
3 |
| 24 |
24675532 | Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. | 2014 May |
1 |
| 25 |
25114718 | Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? | 2014 |
3 |
| 26 |
25249538 | Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. | 2014 Sep 30 |
1 |
| 27 |
23224399 | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. | 2013 Feb 1 |
2 |
| 28 |
23543055 | Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. | 2013 May |
2 |
| 29 |
23569315 | Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. | 2013 May 10 |
1 |
| 30 |
23843024 | Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. | 2013 Oct |
2 |
| 31 |
23940356 | Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. | 2013 Aug 27 |
1 |
| 32 |
22011930 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. | 2012 Mar |
4 |
| 33 |
22325452 | Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. | 2012 Feb 10 |
1 |
| 34 |
22872574 | Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. | 2012 Oct 1 |
1 |
| 35 |
21482676 | ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. | 2011 Jun 1 |
2 |
| 36 |
21499296 | Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. | 2011 Oct 6 |
1 |
| 37 |
21685235 | Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. | 2011 Aug |
2 |
| 38 |
21816844 | Targeting the HER/EGFR/ErbB family to prevent breast cancer. | 2011 Aug |
2 |
| 39 |
22190871 | Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer. | 2011 |
2 |
| 40 |
20459769 | Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. | 2010 May 11 |
5 |
| 41 |
19141783 | Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. | 2009 Jan 21 |
1 |
| 42 |
19536776 | The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. | 2009 Dec 15 |
4 |
| 43 |
19554571 | Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. | 2009 Oct |
4 |
| 44 |
18334220 | Mechanism of activation and inhibition of the HER4/ErbB4 kinase. | 2008 Mar |
4 |
| 45 |
18413839 | EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. | 2008 Apr 15 |
2 |
| 46 |
18664652 | Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. | 2008 Aug 6 |
7 |
| 47 |
19047120 | Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. | 2008 Dec 1 |
1 |
| 48 |
17203189 | Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. | 2007 Feb |
1 |